secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001551152-25-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.
- Net revenues $15.776B, up 9.1% reported (8.4% operational); Immunology $7.885B (+11.9%) led by Skyrizi $4.708B (+46.8%).
- Raises 2025 adjusted diluted EPS guidance to $10.61-$10.65 (from $10.38-$10.58); includes $2.05/share YTD IPR&D impact.
- Quarterly dividend increased 5.5% to $1.73/share, payable Feb 17, 2026 to holders of record Jan 16, 2026.
- Oncology $1.682B (-0.3%); Aesthetics $1.193B (-3.7%); Neuroscience $2.841B (+20.2%); Vraylar $934M, Botox Therapeutic $985M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/0001551152-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20251031.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer